31.8% in favor
Proposal asking the Board of Directors to report to shareholders on whether and how JNJ subsidiary Janssen’s receipt of public financial support for development and manufacture of vaccines and therapeutic for COVID-19 is being, or will be, taken into account when engaging in conduct that affects access to such products, such as setting prices.
We and selected third parties use cookies or similar technologies for technical purposes and, with your consent, for other purposes. You can consent to the use of such technologies by using the “Accept” button, by closing this notice, by scrolling this page, by interacting with any link or button outside of this notice or by continuing to browse otherwise.